We examined whether activated protein C (APC) is an effective conjunctive therapy to thrombolysis in patients with ST-segment-elevated acute myocardial infarction (AMl). BACKGROUND Activated protein C possesses both systemic anticoagulant and anti-inflammatory properties.
Protein C is one of the most important physiologic anticoagulant components (1, 2) . After activation by thrombinthrombomodulin complexes on the membrane surface of platelets and endothelial cells, protein C is converted to activated protein C (APC), which inactivates factors Va and VIIIa (3, 4) . These properties of APC are thought to be eligible for a therapeutic strategy against thrombotic disorders. In fact, APC has favorable effects on a murine model of ischemic stroke (5) and a rat model of mesenteric arteriolar thrombosis (6) . Activated protein C has also been shown to inactivate type 1 plasminogen activator inhibitor (PAI-1), thereby promoting fibrinolysis (7, 8) . When released from activated platelets, PAI-1 is thought to be involved in the formation of microthrombus by inhibiting clot lysis (9) , and that may cause reocclusion of coronary arteries after thrombolytic therapy in patients with acute myocardial infraction (AMI).
We have previously demonstrated that APC is more effective than heparin in preventing arterial reocclusion after thrombolysis in a canine model of coronary artery thrombosis (10) . We have also reported that the endogenous APC level is elevated in patients with AMI, and the levels were higher in cases with unsuccessful thrombolysis, suggesting that APC generation might be accelerated in response to the increased thrombin generation in those cases (11) . From these observations, we hypothesized that therapeutic administration of exogenous APC might be useful as a conjunctive therapy to enhance the effects of thrombolysis in patients with AMI.
To examine this hypothesis, we investigated the effect of APC conjunctively administered after thrombolysis with recombinant tissue-type plasminogen activator (t-PA) in patients with AMI. The effects were compared with those of conventional conjunctive therapy using unfractionated heparin in a randomized fashion.
METHODS
The schematic summarization of the study protocol of the present study is shown in Figure 1 .
Patients.
We studied 19 consecutive patients with first ST-segment-elevated AMI successfully treated with recombinant t-PA. Patients were admitted to our institutions within 6 h after symptom onset. All had ischemic symptoms lasting Ն30 min and met the following electrocardiographic (ECG) criteria: ST-segment elevation Ն0.1 mV in two or more limb leads or ST-segment elevation Ն0.2 mV in two or more contiguous precordial leads. Written, informed consent was obtained from each patient and his or her family. The study protocol was in agreement with the guidelines of the ethics committee at our institutions. Thrombolysis. All patients underwent emergent coronary angiography (CAG) immediately after they were diagnosed as having AMI. Patients with cardiogenic shock and a contraindication to thrombolytic therapy (active peptic ulceration, previous intracerebral hemorrhage, surgical operation, significant trauma, or head injury within the last four weeks) were excluded from this study, and instead of thrombolysis, coronary angioplasty was selected for reperfusion therapy. All patients received 81 mg oral aspirin and an intravenous bolus administration of 100 U/kg unfractionated heparin (heparin sodium, Shimizu Pharmaceutical Co., Ltd., Shizuoka, Japan) before CAG. After confirming the total occlusion of an infarct-related coronary artery, corresponding to the ST-segment-elevated leads on the ECG, the patients underwent thrombolytic therapy with the recombinant t-PA called alteplase (GRTPA, Tanabe Seiyaku Co., Ltd., Osaka, Japan). Alteplase was administered intravenously at 0.5 to 0.75 mg/kg. Ten percent of the total dose was administered as an intravenous bolus, followed by drip infusion of the rest over 60 min. The maximum total dose is recommended not to exceed 41.4 mg (24 million IU). Infusion was stopped when Thrombolysis In Myocardial Infarction trial flow grade 3, confirmed by repeated CAG with continuous 12-lead ECG monitoring, was obtained. Conjunctive therapy. Patients were randomly assigned to receive one of the following two intravenous conjunctive therapies during 48 h after thrombolysis: unfractionated heparin, 100 to 400 U/kg per day, adjusted to maintain an activated partial thromboplastin time (aPTT) at 1.5 to 2 times the control level (heparin group, n ϭ 10), or human plasma-derived APC, 0.06 mg/kg per day (APC group, n ϭ 9). The randomized conjunctive therapy was begun immediately after the completion of thrombolysis. Table 1 shows the baseline patient characteristics of the two conjunctive treatment groups. Activated protein C. Human plasma-derived APC (CTC-111) was kindly provided by the Chemo-SeroTherapeutic Research Institute (Kumamoto, Japan). The manufacturing process of APC is briefly described as follows. Protein C was purified from freshly prepared citrated human plasma by immunoaffinity chromatography using the anti-protein C monoclonal antibody column. After activation of protein C by human thrombin, APC was purified to homogeneity, essentially as described by Taylor et al. (12) . Purified APC displayed a single peak on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The purified preparation of APC was pasteurized by heating at 65°C for 96 h in a dry state. No significant change was observed in the crossed immunoelectrophoresis, circular dichroic spectra, ultraviolet absorption spectrum, and fluorescence spectrum after heat treatment. Figure 1 . Schematic summarization of the study protocol. All patients were treated with a bolus injection of 100 U/kg heparin followed by a drip infusion of recombinant tissue-type plasminogen activator (alteplase). The patients were then randomly assigned to receive heparin or activated protein C intravenously for 48 h. AMI ϭ acute myocardial infarction.
Abbreviations and Acronyms

AMI
ϭ acute myocardial infarction anti-PC MAb ϭ anti-human protein C monoclonal antibody APC ϭ activated protein C aPTT ϭ activated partial thromboplastin time BSA ϭ bovine serum albumin CAG ϭ coronary angiography ECG ϭ electrocardiogram/electrocardiographic PAI-1 ϭ type 1 plasminogen activator inhibitor TBS ϭ tris buffered saline TNF ϭ tumor necrosis factor t-PA ϭ tissue-type plasminogen activator
Blood sampling. All patients were treated in the intensive care unit during conjunctive treatments (48 h). Any evidences of adverse events, including reocclusion of the recanalized coronary arteries and intra-and/or extracorporeal bleeding, were carefully monitored. Venous blood was collected to detect peak serum creatine kinase (CK) and CK-MB levels, and following coagulation and fibrinolytic parameters; plasma levels of t-PA antigen, PAI activity, APC antigen and aPTT. Blood sampling was performed on hospital admission (pretreatment) and 4, 8, 12, 24, 48 , and 72 h after the start of conjunctive treatments. At the time of sampling, the initial 3 ml blood was discarded, and the subsequent 2 ml venous blood was collected in a sequential manner into an evacuated tube containing 0.3 mol/l benzamidine for measurement of APC, and 3 ml venous blood was collected into an evacuated tube containing 0.5 ml sodium citrate (0.13 mol/l, pH 7.5) for measurement of t-PA antigen, PAI activity, and aPTT. All blood samples were centrifuged at 3,000 rpm for 10 min at 4°C, and divided plasma was stored at Ϫ80°C until analyzed. Measurements of t-PA, PAI, APC, and aPTT. Plasma t-PA antigen levels were measured by commercially available enzyme-linked immunosorbent assay kits produced by Diagnostica Stago, Inc. (Francoville, France) (13) . Intraand interassay coefficients of variation in this assay were 2.4% and 4.7%, respectively. The control value for t-PA antigen in our laboratory (n ϭ 35) was 5.8 Ϯ 1.7 ng/ml (mean Ϯ SD). Activity levels of PAI were also measured by commercial chromogenic single-point poly-D-lysine-stimulated assay kits produced by Biopool Inc. (Umeå, Sweden) (14) . Intraand interassay coefficients of variation in this assay were 9.4% and 11.4%, respectively. The control value for PAI activity in our laboratory (n ϭ 35) was 5.4 Ϯ 4.1 IU/ml (mean Ϯ SD).
Plasma APC levels were measured by enzyme capture assay with slight modifications of the method previously reported by Gruber and Griffin (15) . An enzyme capture assay for APC was performed as follows: polystyrene balls were dipped in anti-human protein C monoclonal antibody (anti-PC MAb; JTC-4) (16) in phosphate-buffered saline (20 mg/ml) and incubated at 4°C overnight. Immobilization was terminated by rinsing the balls three times, followed by coating them with 1% bovine serum albumin (BSA)/ phosphate-buffered saline at 4°C for two days. Plasma samples were diluted at 1:160 with 0.5% BSA/tris buffered saline (TBS). Standard APC, which was purified by affinity purification from human plasma using immobilized anti-PC MAb, was kindly provided by the Chemo-SeroTherapeutic Research Institute. The APC standards were prepared at concentrations of 0.2, 0.1, 0.05, 0.02, 0.01, and 0.005 g/ml, with protein C-deficient pooled normal human plasma diluted at 1:160 with 0.5% BSA/TBS. Each sample and the APC standards (400 l) were incubated in the anti-PC MAb-fixed balls. After incubation at 37°C for 2 h, the balls were washed twice with TBS and then incubated with 400 l of 0.05 mol/l tris-HCl buffer (pH 8.5) containing a fluorogenic peptide substrate (Peptide Institute Inc., Osaka, Japan) at 4°C overnight (17) . The enzyme-substrate reaction was terminated by adding 1 ml of 0.01 mol/l acetic acid, and the fluorescence intensity was measured (excitation 380 nm, emission 460 nm). Intra-and interassay coefficients of variation in this assay were 8.1% and 3.5%, respectively. The control value for APC in our laboratory (nϭ 23) was 1.3 Ϯ 1.4 ng/ml (mean Ϯ SD).
The aPTT was determined with an automated clot timer and commercially available reagents. Statistical analyses. Because the values obtained from this study were not normally distributed, all data are shown as median values [ranges] instead of mean values Ϯ SD, unless otherwise noted. Because of the same considerations, nonparametric tests were used as statistical analyses. The clinical characteristics between the APC-and heparin-treated groups were compared using the Mann-Whitney U test for continuous data, and the chi-square test for frequency data. The time course of plasma t-PA, PAI, and APC levels and aPTT in each conjunctive treatment group was analyzed by a Friedman test followed by a multiple Wilcoxon signed rank test if H 0 was rejected. More specifically, probability levels were adjusted according to the following formula:
k (i.e., the Dunn-Sidak method; p k ϭ adjusted p values; p o ϭ original p values; k ϭ number Continuous data are shown as the median value (range), and the other data as the number (%) of patients. APC ϭ activated protein C; BMI ϭ body mass index; CK ϭ creatine kinase.
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Activated Protein C After Thrombolysis in AMI of tests made). Those parameters between the two conjunctive treatment groups at a specific sampling point were analyzed by the Mann-Whitney U test. Probability levels Ͻ0.05 were considered significant.
RESULTS
Patient characteristics and clinical course.
There were no significant differences in the baseline patient characteristics and clinical courses between the two conjunctive treatment groups ( Table 1) . Reocclusion of the recanalized infarctrelated coronary arteries was observed in one patient in the heparin group. The patient complained of chest pain at about 8 h after the start of heparin, and the ECG revealed ST-segment re-elevation in the same leads, as recorded on admission. Rescue coronary angioplasty was performed for the recanalization of the reoccluded coronary artery. On the other hand, none of the patients in the APC group had reocclusion in their recanalized coronary arteries. There were no adverse side effects, including hemorrhagic complications in the APC group, although there were two cases of minor bleeding (one with hematoma at the puncture site and macroscopic hematuria; the other with macroscopic hematuria alone), and one case of major bleeding required surgical repair (postperitoneal hematoma) in the heparin group. In this way, total adverse events occurred more frequently in the heparin group than in the APC group (p ϭ 0.033). Hemostatic parameters. Plasma APC levels (ng/ml) were significantly increased in the APC group during drip infusion (4 to 24 h, p Ͻ 0.05 vs. control), and the peak level reached more than 10 times the control level (Fig. 2) . In the heparin group, aPTT was significantly prolonged at 8 h and 12 h, as compared with the same sampling points in the APC group. An aPTT in the heparin group was prolonged 4 to 12 h, as compared with the pretreatment level, whereas no significant changes were observed in the APC group (Fig. 3) . Plasma PAI activity (IU/ml) was increased in both groups on admission (12. (Fig. 4) .
Plasma t-PA antigen levels (ng/ml) were significantly elevated until 8 h in the APC group and until 24 h in the heparin group. The t-PA antigen levels were significantly higher in the heparin group than in the APC group at 24 and 48 h (Fig. 5) .
Changes in plasma PAI activity at each of six sampling points from the pretreatment levels had an obvious relationship with those of plasma APC levels, although the relationship was not so strong. In other words, the more the plasma APC level increased, the more the plasma PAI activity decreased (Fig. 6 ).
DISCUSSION
In this study, for the first time, we showed that administration of APC could be a useful conjunctive therapy after thrombolysis with recombinant t-PA in patients with AMI. The effects of APC after thrombolysis, at least during first several hours, might be the overlap effects of both heparin and APC, because bolus heparin was administered to all the study patients.
Anticoagulant effects of APC. Reocclusion of the recanalized coronary artery in the early phase of AMI occurs 10% to 20% of patients, and that causes deterioration of the efficacy of reperfusion therapy (18, 19) . Protein C is one of most important physiologic antithrombotic components (1, 2) . After activation by thrombin-thrombomodulin complexes on the endothelial cells, APC inactivates factors Va and VIIIa in the presence of protein S and phospholipids, which are the main constituents of the plasma membrane of platelets and endothelial cells (3, 4) . This means that APC acts as an anticoagulant at just the sites of thrombus generation, and it might be more effective for conjunctive therapy if administered after thrombolysis. In a canine model of coronary artery thrombosis, APC has superiority over heparin to suppress thrombotic reocclusion after recanalization with recombinant t-PA, without any hemorrhagic complications (10) . The effects of APC were also confirmed in human AMI cases from the results of this study. Profibrinolytic effects of APC. Type 1 plasminogen activator inhibitor is an important controller of net fibrinolytic activity, and plasma PAI-1 levels are increased in most AMI cases (20 -22) . However, in AMI cases with spontaneously recanalized infarct-related coronary arteries at emergent CAG on admission, plasma PAI activity was not increased (21) . In a rabbit carotid artery thrombosis model, Fujii et al. (22) reported that plasma PAI-1 activity was increased after t-PA-induced recanalization of completely occluded vessels. On the other hand, we have reported that PAI activity is increased 4 h after thrombolytic therapy with alteplase and remains high during the first 24 h, though not in the cases with angioplasty (23) . In this way, it is important to inhibit PAI-1 elevation in patients with AMI, particularly after thrombolysis. Activated protein C is known to be a unique anticoagulant because it enhances clot lysis by inhibiting PAI-1 activity in endothelial cell cultures and in clot lysis assay (7, 8) . Similarly, elevation of PAI activity was significantly suppressed by APC in the present study. Furthermore, it is reported that APC inhibited the production of tumor necrosis factor-␣ (TNF-␣), which is known to Correlations between changes in plasma PAI activity from the pretreatment levels and those of plasma activated protein C (APC) levels at each of six sampling points after thrombolysis in the APC group.
